Aptose Biosciences (NASDAQ:APTO) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Trading Down 2.0 %

NASDAQ:APTO opened at $0.24 on Tuesday. The stock has a market capitalization of $14.21 million, a P/E ratio of -0.08 and a beta of 1.06. Aptose Biosciences has a 1 year low of $0.13 and a 1 year high of $2.60. The firm has a 50 day moving average of $0.28 and a 200-day moving average of $0.44.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.